Lipocine Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
LPCN$1.59-7.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $(9,627,505) | $8,352 |
| Adjustments to reconcile net income (loss) to cash used in operating activities: | ||
| Depreciation expense | 60,782 | 41,106 |
| Stock-based compensation expense | 242,497 | 408,551 |
| Non-cash gain on change in fair value of warrant liability | - | (17,166) |
| Amortization of discounts on marketable investment securities | (192,938) | (697,865) |
| Changes in operating assets and liabilities: | ||
| Accrued interest income | 106,258 | (68,193) |
| License and royalties receivable | (1,053,985) | 91,405 |
| Prepaid and other current assets | (311,090) | 114,104 |
| Accounts payable | 700,126 | (1,124,281) |
| Accrued expenses | 315,134 | (297,246) |
| Deferred revenue | - | 320,000 |
| Cash used in operating activities | (9,760,721) | (1,221,233) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | - | (90,086) |
| Purchases of marketable investment securities | (14,708,915) | (32,863,853) |
| Maturities of marketable investment securities | 20,600,000 | 35,400,000 |
| Cash provided by investing activities | 5,891,085 | 2,446,061 |
| Cash flows from financing activities: | ||
| Net proceeds from sale of common stock through ATM | 2,869,552 | 209,340 |
| Cash provided by financing activities | 2,869,552 | 209,340 |
| Net increase (decrease) in cash and cash equivalents | (1,000,084) | 1,434,168 |
| Cash and cash equivalents at beginning of period | 6,205,926 | 4,771,758 |
| Cash and cash equivalents at end of period | $5,205,842 | $6,205,926 |
| Supplemental disclosure of cash flow information: | ||
| Income taxes paid | $200 | 681 |
| Supplemental disclosure of non-cash investing and financing activity: | ||
| Net unrealized gain (loss) on available-for-sale securities | $(4,693) | $1,879 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.